Prestige Consumer Healthcare (NYSE:PBH) Given New $97.00 Price Target at Royal Bank of Canada

Prestige Consumer Healthcare (NYSE:PBH) had its price target raised by Royal Bank of Canada from $96.00 to $97.00 in a research note released on Friday,Benzinga reports. They currently have a sector perform rating on the stock.

PBH has been the subject of several other reports. Oppenheimer boosted their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, February 13th. Canaccord Genuity Group boosted their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a report on Friday, February 7th. Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a report on Monday, December 9th. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and an average target price of $93.33.

Prestige Consumer Healthcare Stock Down 0.3 %

Shares of NYSE PBH opened at $84.12 on Friday. The company has a market capitalization of $4.17 billion, a price-to-earnings ratio of 19.70, a price-to-earnings-growth ratio of 2.69 and a beta of 0.46. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. The business has a 50-day moving average of $82.46 and a two-hundred day moving average of $78.59. Prestige Consumer Healthcare has a 1 year low of $62.35 and a 1 year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. On average, analysts forecast that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now owns 17,157 shares in the company, valued at approximately $1,544,130. The trade was a 8.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently added to or reduced their stakes in PBH. Kayne Anderson Rudnick Investment Management LLC acquired a new position in Prestige Consumer Healthcare during the 4th quarter worth approximately $84,932,000. Raymond James Financial Inc. acquired a new stake in shares of Prestige Consumer Healthcare in the 4th quarter worth approximately $42,593,000. Norges Bank acquired a new stake in shares of Prestige Consumer Healthcare in the 4th quarter worth approximately $40,009,000. Bessemer Group Inc. grew its holdings in shares of Prestige Consumer Healthcare by 10,053.1% in the 4th quarter. Bessemer Group Inc. now owns 295,050 shares of the company’s stock worth $23,041,000 after acquiring an additional 292,144 shares during the period. Finally, Boston Trust Walden Corp grew its holdings in shares of Prestige Consumer Healthcare by 43.5% in the 4th quarter. Boston Trust Walden Corp now owns 831,627 shares of the company’s stock worth $64,942,000 after acquiring an additional 252,089 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.